CLINE J MICHAEL 4

Accession 0001209191-20-041794

CIK 0001481646other

View on SEC.gov Company Profile

Filed

Jul 7, 8:00 PM ET

Accepted

Jul 10, 6:42 AM ET

Size

98.8 KB

Accession

0001209191-20-041794

Insider Transaction Report

Form 4

Period: 2020-07-07

Accolade, Inc.ACCD

CLINE J MICHAEL

Director10% Owner

Transactions

Conversion
Common Stock
2020-07-07+31,357→ 121,091 total(indirect: By Partnership)
Conversion
Common Stock
2020-07-07+1→ 128,961 total(indirect: By Partnership)
Conversion
Common Stock
2020-07-07+978,566→ 2,291,834 total(indirect: By Accretive II, L.P.)
Conversion
Common Stock
2020-07-07+1,794,034→ 1,794,034 total(indirect: By Accretive Investors SBIC, LP)
Conversion
Common Stock
2020-07-07+274,586→ 4,499,444 total(indirect: By Accretive Investors SBIC, LP)
Conversion
Series C Preferred Stock
2020-07-07−5,146→ 0 total(indirect: By Partnership)
→ Common Stock (7,869 underlying)
Conversion
Series A-1 Preferred Stock
2020-07-07−378,186→ 0 total(indirect: By LLC)
→ Common Stock (426,473 underlying)
Conversion
Series A-2 Preferred Stock
2020-07-07−306,871→ 0 total(indirect: By LLC)
→ Common Stock (360,936 underlying)
Conversion
Series C Preferred Stock
2020-07-07−45,061→ 0 total(indirect: By LLC)
→ Common Stock (68,910 underlying)
Conversion
Series A-2 Preferred Stock
2020-07-07−271,999→ 0 total(indirect: By Accretive II Coinvestment, L.P.)
→ Common Stock (319,920 underlying)
Conversion
Common Stock
2020-07-07+273,901→ 1,061,310 total(indirect: By LLC)
Conversion
Common Stock
2020-07-07+319,920→ 749,264 total(indirect: By Accretive II Coinvestment, L.P.)
Conversion
Common Stock
2020-07-07+1,313,268→ 1,313,268 total(indirect: By Accretive II, L.P.)
Conversion
Common Stock
2020-07-07+1,336,804→ 3,130,838 total(indirect: By Accretive Investors SBIC, LP)
Conversion
Common Stock
2020-07-07+3→ 4,499,447 total(indirect: By Accretive Investors SBIC, LP)
Conversion
Series A-1 Preferred Stock
2020-07-07−45,598→ 0 total(indirect: By Partnership)
→ Common Stock (51,420 underlying)
Conversion
Series C Preferred Stock
2020-07-07−179,553→ 0 total(indirect: By Accretive Investors SBIC, LP)
→ Common Stock (274,586 underlying)
Conversion
Common Stock
2020-07-07+426,473→ 426,473 total(indirect: By LLC)
Conversion
Common Stock
2020-07-07+360,936→ 787,409 total(indirect: By LLC)
Conversion
Common Stock
2020-07-07+1,094,020→ 4,224,858 total(indirect: By Accretive Investors SBIC, LP)
Conversion
Series A-2 Preferred Stock
2020-07-07−32,575→ 0 total(indirect: By Partnership)
→ Common Stock (38,314 underlying)
Conversion
Common Stock
2020-07-07+68,910→ 1,130,220 total(indirect: By LLC)
Conversion
Common Stock
2020-07-07+429,344→ 429,344 total(indirect: By Accretive II Coinvestment, L.P.)
Conversion
Common Stock
2020-07-07+261,818→ 1,011,082 total(indirect: By Accretive II Coinvestment, L.P.)
Conversion
Common Stock
2020-07-07+1→ 1,076,796 total(indirect: By Accretive II Coinvestment, L.P.)
Conversion
Common Stock
2020-07-07+800,845→ 3,092,679 total(indirect: By Accretive II, L.P.)
Conversion
Series B Preferred Stock
2020-07-07−26,356→ 0 total(indirect: By Partnership)
→ Common Stock (31,357 underlying)
Conversion
Series B Preferred Stock
2020-07-07−230,215→ 0 total(indirect: By LLC)
→ Common Stock (273,901 underlying)
Conversion
Series A-1 Preferred Stock
2020-07-07−380,732→ 0 total(indirect: By Accretive II Coinvestment, L.P.)
→ Common Stock (429,344 underlying)
Conversion
Series A-1 Preferred Stock
2020-07-07−1,164,574→ 0 total(indirect: By Accretive II, L.P.)
→ Common Stock (1,313,268 underlying)
Conversion
Series A-2 Preferred Stock
2020-07-07−831,986→ 0 total(indirect: By Accretive II, L.P.)
→ Common Stock (978,566 underlying)
Conversion
Series A-2 Preferred Stock
2020-07-07−1,136,563→ 0 total(indirect: By Accretive Investors SBIC, LP)
→ Common Stock (1,336,804 underlying)
Conversion
Common Stock
2020-07-07+51,420→ 51,420 total(indirect: By Partnership)
Conversion
Common Stock
2020-07-07+38,314→ 89,734 total(indirect: By Partnership)
Conversion
Common Stock
2020-07-07+7,869→ 128,960 total(indirect: By Partnership)
Conversion
Common Stock
2020-07-07+1→ 1,130,221 total(indirect: By LLC)
Conversion
Common Stock
2020-07-07+65,713→ 1,076,795 total(indirect: By Accretive II Coinvestment, L.P.)
Conversion
Common Stock
2020-07-07+201,002→ 3,293,681 total(indirect: By Accretive II, L.P.)
Conversion
Common Stock
2020-07-07+2→ 3,293,683 total(indirect: By Accretive II, L.P.)
Conversion
Series C Preferred Stock
2020-07-07−42,970→ 0 total(indirect: By Accretive II Coinvestment, L.P.)
→ Common Stock (65,713 underlying)
Conversion
Series B Preferred Stock
2020-07-07−673,113→ 0 total(indirect: By Accretive II, L.P.)
→ Common Stock (800,845 underlying)
Conversion
Series C Preferred Stock
2020-07-07−131,436→ 0 total(indirect: By Accretive II, L.P.)
→ Common Stock (201,002 underlying)
Conversion
Series B Preferred Stock
2020-07-07−919,528→ 0 total(indirect: By Accretive Investors SBIC, LP)
→ Common Stock (1,094,020 underlying)
Conversion
Series B Preferred Stock
2020-07-07−220,059→ 0 total(indirect: By Accretive II Coinvestment, L.P.)
→ Common Stock (261,818 underlying)
Conversion
Series A-1 Preferred Stock
2020-07-07−1,590,905→ 0 total(indirect: By Accretive Investors SBIC, LP)
→ Common Stock (1,794,034 underlying)

Footnotes (14)

[F1]The Series A-1 Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 1:1.127681818 basis immediately upon closing of the Issuer's initial public offering and had no expiration date.
[F10]Under the terms of the Issuer's Seventh Amended and Restated Certificate of Incorporation, no fractional shares were issued upon the conversion of any share or shares of its Preferred Stock after aggregating all shares owned thereof. This 1 share represents the aggregate total of all fractional shares that Accretive II Coinvestment, L.P. was entitled to receive following the conversion of the Preferred Stock that it held.
[F11]The shares reported herein are held of record by Accretive II, L.P. Accretive II GP, LLC is the general partner of Accretive II, L.P. The Reporting Person and Edgar Bronfman, Jr. are the managing members of Accretive II GP, LLC, and may be deemed to have shared voting and dispositive power with respect to the shares held by Accretive II, L.P. The Reporting Person disclaims beneficial ownership of such securities.
[F12]Under the terms of the Issuer's Seventh Amended and Restated Certificate of Incorporation, no fractional shares were issued upon the conversion of any share or shares of its Preferred Stock after aggregating all shares owned thereof. These 2 shares represent the aggregate total of all fractional shares that Accretive II, L.P. was entitled to receive following the conversion of the Preferred Stock that it held.
[F13]The shares reported herein are held of record by Accretive Investors SBIC, L.P. Accretive Associates SBIC, LLC is the general partner of Accretive Investors SBIC, L.P. The Reporting Person and Edgar Bronfman, Jr. are the managing members of Accretive Associates SBIC, LLC, and may be deemed to have shared voting and dispositive power with respect to the shares held by Accretive Investors SBIC, L.P. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.
[F14]Under the terms of the Issuer's Seventh Amended and Restated Certificate of Incorporation, no fractional shares were issued upon the conversion of any share or shares of its Preferred Stock after aggregating all shares owned thereof. These 3 shares represent the aggregate total of all fractional shares that Accretive Investors SBIC, LP was entitled to receive following the conversion of the Preferred Stock that it held.
[F2]The shares reported herein are held of record by Accretive Care Holding Partnership. Accretive II GP, LLC is the general partner of Accretive Care Holding Partnership. The Reporting Person and Edgar Bronfman, Jr. are the managing members of Accretive II GP, LLC, and may be deemed to have shared voting and dispositive power with respect to the shares held by Accretive Care Holding Partnership. The Reporting Person disclaims beneficial ownership of such securities.
[F3]The Series A-2 Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 1:1.176181818 basis immediately upon closing of the Issuer's initial public offering and had no expiration date.
[F4]The Series B Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 1:1.18976363636364 basis immediately upon closing of the Issuer's initial public offering and had no expiration date.
[F5]The Series C Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 1:1.52927954545455 basis immediately upon closing of the Issuer's initial public offering and had no expiration date.
[F6]Under the terms of the Issuer's Seventh Amended and Restated Certificate of Incorporation, no fractional shares were issued upon the conversion of any share or shares of its Preferred Stock after aggregating all shares owned thereof. This 1 share represents the aggregate total of all fractional shares that Accretive Care Holding Partnership was entitled to receive following the conversion of the Preferred Stock that it held.
[F7]The shares reported herein are held of record by Accretive Coinvestment Partners, LLC. Accretive Associates I, LLC is the managing member of Accretive Coinvestment Partners, LLC. The Reporting Person and Edgar Bronfman, Jr. are the managing members of Accretive Associates I, LLC, and may be deemed to have shared voting and dispositive power with respect to the shares held by Accretive Coinvestment Partners, LLC. The Reporting Person disclaims beneficial ownership of such securities.
[F8]Under the terms of the Issuer's Seventh Amended and Restated Certificate of Incorporation, no fractional shares were to be issued upon the conversion of any share or shares of its Preferred Stock after aggregating all shares owned thereof. This 1 share represents that aggregate total of all fractional shares that Accretive Coinvestment Partners, LLC was entitled to receive following the conversion of the Preferred Stock that it held.
[F9]The shares reported herein are held of record by Accretive II Coinvestment, L.P. Accretive II GP, LLC is the general partner of Accretive II Coinvestment, L.P. The Reporting Person and Edgar Bronfman, Jr. are the managing members of Accretive II GP, LLC, and may be deemed to have shared voting and dispositive power with respect to the shares held by Accretive II Coinvestment, L.P. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

Documents

1 file

4
doc4.xmlPrimary
FORM 4 SUBMISSION

Issuer

Accolade, Inc.

CIK 0001481646

→

Entity typeother

Related Parties

filerCIK 0001201677

Filing Metadata

Form type: 4
Filed: Jul 7, 8:00 PM ET
Accepted: Jul 10, 6:42 AM ET
Size: 98.8 KB

View on SEC.gov